Shares of Viking Therapeutics (VKTX) are in the spotlight on Thursday after Roche (RHHBY) announced results from Genentech’s Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. While acknowledging that… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3920546/-Viking-seen-holding-up-against-obesity-competition-as-Roche-presents-data)
previous post